Aptevo Therapeutics Stock Plummets to New 52-Week Low of $1.32

Aptevo Therapeutics, Inc., a player in the Pharmaceuticals & Biotechnology sector, has recently reached a new 52-week low of USD 1.32 on September 17, 2025. This significant decline highlights the stock's current market position, particularly in light of its market capitalization of USD 5 million.
The company is currently operating at a loss, as indicated by the absence of a price-to-earnings (P/E) ratio. In comparison, the industry P/E is also not applicable, reflecting broader challenges within the sector. Aptevo's financial metrics reveal a debt-to-equity ratio of -1.44, suggesting a negative equity position, while the return on equity stands at a notably low -368.26%.

Additionally, the stock's price-to-book ratio is recorded at 0.75, indicating that the market values the company at less than its book value. The stock's previous 52-week high was significantly higher at USD 381.1, marking a stark contrast to its current valuation. This recent activity underscores the ongoing volatility and challenges faced by Aptevo Therapeutics in the competitive biotechnology landscape.